These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 26683361)

  • 1. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
    Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
    Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest.
    Schaaf L; Schwab M; Ulmer C; Heine S; Mürdter TE; Schmid JO; Sauer G; Aulitzky WE; van der Kuip H
    Cancer Res; 2016 May; 76(10):2868-75. PubMed ID: 27013194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
    Pavan S; Olivero M; Corà D; Di Renzo MF
    Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
    Cho HJ; Kim IK; Park SM; Baek KE; Nam IK; Park SH; Ryu KJ; Choi J; Ryu J; Hong SC; Jeong SH; Lee YJ; Ko GH; Kim J; Won Lee C; Soo Kang S; Yoo J
    Int J Cancer; 2014 Oct; 135(7):1553-63. PubMed ID: 24585459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
    Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
    Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells.
    Li B; Gao Y; Rankin GO; Rojanasakul Y; Cutler SJ; Tu Y; Chen YC
    Cancer Lett; 2015 Jan; 356(2 Pt B):418-33. PubMed ID: 25304379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-1 attenuates cisplatin-induced gammaH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer.
    Jeon JH; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
    Cancer Lett; 2008 Dec; 272(2):232-41. PubMed ID: 18762365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):132-5. PubMed ID: 18683754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers.
    Li F; Shanmugam MK; Siveen KS; Wang F; Ong TH; Loo SY; Swamy MM; Mandal S; Kumar AP; Goh BC; Kundu T; Ahn KS; Wang LZ; Hui KM; Sethi G
    Oncotarget; 2015 Mar; 6(7):5147-63. PubMed ID: 25762616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
    Li CC; Yang JC; Lu MC; Lee CL; Peng CY; Hsu WY; Dai YH; Chang FR; Zhang DY; Wu WJ; Wu YC
    Oncotarget; 2016 Jan; 7(2):1947-59. PubMed ID: 26657501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
    Koussounadis A; Langdon SP; Um I; Kay C; Francis KE; Harrison DJ; Smith VA
    BMC Cancer; 2016 Mar; 16():205. PubMed ID: 26964739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells.
    Gery S; Xie D; Yin D; Gabra H; Miller C; Wang H; Scott D; Yi WS; Popoviciu ML; Said JW; Koeffler HP
    Clin Cancer Res; 2005 Oct; 11(20):7243-54. PubMed ID: 16243794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
    Liu J; Wan L; Lu K; Sun M; Pan X; Zhang P; Lu B; Liu G; Wang Z
    PLoS One; 2015; 10(5):e0114586. PubMed ID: 25992654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.
    Huang X; Okafuji M; Traganos F; Luther E; Holden E; Darzynkiewicz Z
    Cytometry A; 2004 Apr; 58(2):99-110. PubMed ID: 15057963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
    Chung YL; Lee MY; Pui NN
    Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
    Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
    Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin knockdown enhances gastric cancer cell sensitivity to radiation and chemotherapy in vitro and in nude mice.
    Shen X; Zheng JY; Shi H; Zhang Z; Wang WZ
    Am J Med Sci; 2012 Jul; 344(1):52-8. PubMed ID: 22261621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.